Its soluble form was elevated in serum from MM patients compared with that from healthy donors, and patients with high levels of soluble BCMA had shorter progression-free survival (PFS) and overall survival (OS) times than those with low levels [5, 13]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.